China-based firms AusperBio and Asymchem (SHE: 002821, HKG: 6821) have entered into a strategic partnership focusing on new drug R&D technical services, drug administration and regulation consultation, brand linkage communication, and more. This collaboration aims to enhance their capabilities in the pharmaceutical sector by leveraging each other’s strengths.
Background of the Partnership
The partnership builds on an existing collaboration where the two companies have worked together on one-stop services. These services span from the development of process/prescriptions of raw materials and preparations of drugs in the field of small nucleic acids, pharmacokinetics, and toxicology research, to the development and application of new varieties of biological drugs, and the research of drugs and clinical services.
Notable Achievements
In October 2022, Asymchem’s CDMO unit facilitated the clinical trial approval for MY-586, a nasal spray COVID-19 neutralizing antibody developed by AusperBio’s joint venture. This achievement highlights the successful collaboration between the two companies in advancing innovative drug solutions.
Significance of the Partnership
This strategic partnership between AusperBio and Asymchem underscores their commitment to advancing the development of new drugs and improving the regulatory landscape for pharmaceuticals. By combining their expertise, the companies aim to accelerate the development and commercialization of innovative therapies, ultimately benefiting patients and the healthcare industry.-Fineline Info & Tech
